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variables have been developed for better stratiﬁcation of
patients before allogeneic hematopoietic cell transplantation
(HCT). The HCT-speciﬁc comorbidity index (CI) captures in-
formation on the number and severity of pretransplantation
comorbidities to predict risks for nonrelapse (NRM) and
overall mortality [1]. The European Group for Blood and
Marrow Transplantation (EBMT) model utilizes a mix of pa-
tient- and disease-speciﬁc risk factors to predict survival
probabilities [2]. Both models have been validated separately
in previous studies [3,4].
Further improvement in predicting NRM and survival
has been shown by combining the HCT-CI with other pa-
tient-speciﬁc risk variables, such as Karnofsky performance
status [5], C-reactive protein [6], or age [7]. Alternatively,
the HCT-CI has been combined with a disease-speciﬁc fac-
tor, such as pre-HCT status of acute myeloid leukemia or
myelodysplastic syndromes, to improve prognostication for
survival [8].
Our colleagues in Barcelona, Spain, integrated 2 estab-
lishedmodels, theHCT-CI and the EBMTscore, into 1, and they
assessed its impact on outcomes of 442 recipients of reduced-
intensity allogeneic HCT [9]. They made 3 conclusions based
on their data: the EBMT score did not further stratify risks of
NRM and survival within HCT-CI risk groups of 0 or 1 to 2, the
addition of the EBMT model was only of beneﬁt in reﬁningFinancial disclosure: See Acknowledgments on page 1456.
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HCT-CI scores of  3 but EBMT scores < 4 had similar out-
comes to those with HCT-CI scores of 1 to 2, regardless of
EBMT scores. The study had a number of limitations because
of its modest sample size. The EBMT score was not signiﬁ-
cantly associated with risks of NRM (P ¼ .10) or survival (P ¼
.20) in a multivariate model, a ﬁnding that could have been a
contraindication for integrating the EBMTscorewith theHCT-
CI. Even though the authors suggested that the HCT-CI had
better discriminative capacity than the EBMT score, the dif-
ference in c-statistic estimates was not statistically signiﬁcant
(P ¼ .10). Finally, the authors did not demonstrate that
combining both models resulted in statistically signiﬁcant
improvement in c-statistic estimates, which is a key analysis
before encouraging future use of the integrated model.
Here, we wanted to address those limitations by
assessing the performance of the combined model in a
relatively larger (N ¼ 1616) and more diverse cohort of re-
cipients of allogeneic HCT after high-dose, reduced-in-
tensity, or nonmyeloablative conditioning regimens, as
previously deﬁned [10].
In our analysis, both the HCT-CI and EBMT scores were
highly statistically signiﬁcantly associatedwith NRM (P< .0001
for both) and survival (P < .0001 for both). The c-statistic es-
timates for predicting 4-year NRM and survival using the HCT-
CI were highly statistically signiﬁcantly better compared with
the EBMT score (.637 versus .580, P ¼ .0001; .613 versus .558,
P < .0001, respectively). Combining both models resulted in
statistically signiﬁcant improvement in c-statistic estimates for
NRM (.662) and survival (.630) compared with those of the
HCT-CI (P < .0001 for both).
Our results also showed that the EBMT model could
further stratify outcomes within HCT-CI scores of either 0, 1
to 2, or  3 (Table 1, Figure 1). Patients with high HCT-CI
scores but lower EBMT scores continued to experience re-
latively worse outcomes compared with those with lower
HCT-CI scores.
Our results provide strong evidence for the independent
association of the HCT-CI and the EBMT score with NRM and
Table 1
Four-Year Probabilities of Nonrelapse Mortality and Rates of Overall Survival as Stratiﬁed by a Combined Model Comprising the Hematopoietic Cell Trans-
plantationeComorbidity Index and the European Group for Blood and Marrow Transplantation
Group N (%) Nonrelapse Mortality Overall Survival
4-year NRM HR (95% CI) 4-year OS HR (95% CI)
HCT-CI 0; EBMT 4 258 (16) 11% 1.0 72% 1.0
HCT-CI 0; EBMT 4þ 212 (13) 19% 1.74 (1.1-2.7) 61% 1.48 (1.1-2.0)
HCT-CI 1,2; EBMT < 4 248 (15) 16% 1.42 (.9-2.2) 63% 1.42 (1.1-1.9)
HCT-CI 1,2; EBMT 4þ 300 (19) 28% 2.92 (2.0-4.3) 48% 2.29 (1.8-3.0)
HCT-CI 3þ; EBMT < 4 237 (15) 31% 3.40 (2.3-5.1) 40% 2.69 (2.1-3.5)
HCT-CI 3þ; EBMT 4þ 361 (22) 41% 5.13 (3.6-7.4) 30% 3.67 (2.9-4.7)
NRM indicates nonrelapse mortality; HR, hazard ratio; OS, overall survival; HCT-CI, hematopoietic cell transplantationecomorbidity index.
M. ElSawy et al. / Biol Blood Marrow Transplant 20 (2014) 1455e14581456survival. Integrating both models is feasible and beneﬁcial
in stratifying patients into 6 risk groups for these outcomes.
The combined grouping could be used in the clinic to counsel
patients about transplantation and facilitate selection of
conditioning intensity. It could also be used in randomized
or retrospective studies to appropriately adjust treatment
comparisons. Our results also suggest that relatively quite
large datasets are required for robust evaluation of risk
indices, and inferences based on smaller patient groups may
be inaccurate. Along those lines, we would caution against
considering patients with high comorbidity burden asFigure 1. Probabilities of (A) nonrelapse mortality (NRM) and (B) Kaplan-
Meier estimates of overall survival as stratiﬁed by a combined model com-
prising the hematopoietic cell transplantationecomorbidity index (HCT-CI)
and the European Group for Blood and Marrow Transplantation (EBMT).having similar outcomes to those with lower comorbidity
burden based on EBMT risk stratiﬁcation, as our results did
not support this conclusion.
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